Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.44 |
| ▸ | ABL1 | P00519 | 7/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6660236 | 0.86 | CYP19A1 (0.40) | CYP19A1CYP11B1CYP11B2PDE2APDE10A | |
| SCHEMBL6653791 | 0.79 | CYP11B1 (0.43) | CYP19A1CYP11B1CYP11B2CYP17A1CYP1A2 | |
| SCHEMBL6840679 | 0.78 | CYP11B1 (0.52) | CYP19A1CYP11B1CYP11B2ABL1 | |
| SCHEMBL6847482 | 0.78 | CYP11B1 (0.62) | CYP19A1CYP11B1CYP11B2ABL1 | |
| SCHEMBL6659366 | 0.72 | CYP19A1 (0.47) | CYP19A1CYP11B1CYP11B2ABL1PDE2A | |
| SCHEMBL6653056 | 0.72 | CYP11B1 (0.46) | CYP19A1CYP11B1CYP11B2ABL1PDE2A | |
| SCHEMBL6658554 | 0.71 | CYP19A1 (0.48) | CYP19A1CYP11B1CYP11B2PDE2APDE10A | |
| SCHEMBL6656138 | 0.71 | CYP19A1 (0.45) | CYP19A1CYP11B1CYP11B2PDE2APDE10A | |
| SCHEMBL26463427 | 0.69 | CYP11B1 (0.46) | CYP11B1CYP11B2ABL1CYP17A1CYP1A2 | |
| SCHEMBL29466450 | 0.69 | CYP11B1 (0.45) | CYP11B1CYP11B2ABL1PDE2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259888-A1 | Novel 4-aminofuropyrimidines and the use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-12-23 | — | — | US | disclosed |
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | CYP17A1, IDO1, CYP21A2 | CYP19A1 9/4885CYP11B1 30/4885CYP11B2 53/4885 |
| US-20040259888-A1 | Novel 4-aminofuropyrimidines and the use thereof | DPYD, TPMT, TYMP | CYP19A1 2602/4885CYP11B1 120/4885CYP11B2 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.